Alzheimer’s

The Institute’s Breakthrough Alzheimer Treatment

The Institute of Neurological Recovery utilizes a unique, revolutionary, breakthrough treatment for Alzheimer’s disease. This treatment, invented by its founder, Edward Tobinick, M.D., addresses excess brain neuroinflammation. Neuroinflammation shuts down brain circuits, preventing brain cells from communicating properly. Dr. Tobinick’s treatment is designed to neutralize this excessive brain inflammation. The first open-label clinical trial of Dr. Tobinick’s unique PSE treatment for Alzheimer’s disease was begun in 2004, with results published in 2006 (reference 2). It was successful, ushering in a new scientific era by demonstrating rapid neurological improvement, beginning within minutes of the first treatment (references 1, 2, 3, 6, 8, 9, 10).

Note: Treatment results can vary, not all patients respond. See Terms of Use.

Selected video: Rapid improvement in a physician with Alzheimer’s disease after PSE treatment at the INR

Watch on YouTube

Request a Consultation: link: https://www.alzheimerbreakthrough.com/request-consultation/

About Dr. Tobinick

Edward Tobinick

Edward Lewis Tobinick, M.D. is an American physician, inventor, and scientist. He has authored multiple, peer-reviewed, scientific publications in the field of neurology and granted more than 30 U.S. and international patents for his medical inventions. His work has been cited by more than 4000 scientific publications. His inventions include novel methods of drug delivery to selectively enhance the ability of large molecular weight drugs and biologics to reach the brain in therapeutic concentration. His medical discoveries have contributed to our fundamental understanding of brain and neuronal function in health and disease.

References

  1. Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
  2. TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, Hyman Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
  3. Perispinal etanercept for treatment of Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research. 2007 Dec;4(5):550-2.
  4. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Edward Tobinick MD. Medscape J Med. 2008 Jun 10;10(6):135.
  5. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H. Gross MD. BMC Neurology. 2008 Jul 21;8:27.
  6. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Edward Tobinick MD, Hyman Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2.
  7. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. Edward Tobinick MD, K Chen PhD, X Chen PhD. BMC Res Notes. 2009 Feb 27;2:28.
  8. Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. Edward Tobinick MD. CNS Drugs. 2009 Sep 1;23(9):713-25.
  9. Perispinal etanercept for neuroinflammatory disorders. Edward Tobinick MD. Drug Discovery Today. 2009 Feb;14(3-4):168-77.
  10. Perispinal etanercept advances as a neurotherapeutic. Tobinick, E., Expert Review Neurotherapeutics, 2018:1-3.(Free Link to Journal Article).